We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| 4d Pharma Plc | LSE:DDDD | London | Ordinary Share | GB00BJL5BR07 | ORD 0.25P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 16.36 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
By Adria Calatayud
Shares in 4D pharma PLC rose Monday after the company said it has entered into a clinical-trial collaboration and supply agreement with Germany's Merck KGaA and Pfizer Inc. for an oncology treatment.
Under the collaboration, the U.K. pharmaceutical company said it will start a clinical trial this year to evaluate BAVENCIO, a maintenance treatment for urothelial carcinoma co-developed by Merck and Pfizer, in combination with 4D pharma's MRx0518, a biotherapeutic product in development for the treatment of cancer.
The trial will evaluate the combination of BAVENCIO and MRx0518 as a first-line maintenance therapy for patients with locally advanced or metastatic urothelial carcinoma that hasn't progressed with first-line platinum-containing chemotherapy, 4D pharma said.
Urothelial carcinoma is a common type of bladder cancer.
Shares in 4D pharma at 0803 GMT were up 9.1% at 144 pence.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
February 08, 2021 03:26 ET (08:26 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year 4d Pharma Chart |
1 Month 4d Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
